GEN Exclusives

More »

GEN News Highlights

More »
May 11, 2009

Regenerative Sciences Grants NeoStem Exclusive Asia License to Regenexx

Regenerative Sciences Grants NeoStem Exclusive Asia License to Regenexx

Company licenses another use for stem cells

  • NeoStem obtained an exclusive royalty-bearing license for Asia to use Regenerative Sciences process that rapidly grows a patient's own adult stem cells to treat a variety of musculoskeletal diseases. NeoStem will use the Regenexx technology to develop treatments for chronic orthopedic conditions.

    NeoStem provides adult stem cell collection and banking to the general population and recently acquired licenses to use stem cells to treat chronic wounds and for cosmetic facial rejuvenation.ADNFCR-2184-ID-19162590-ADNFCR "The minimally invasive Regenexx procedure complements NeoStem's established in-office stem cell collection procedures and expands our expertise into a new area," says Robin Smith, M.D. and CEO of NeoStem, "Restoring joints, bone, muscle, and cartilage and combating orthopedic diseases complements our growth in the anti-aging and regenerative medicine arena."

    Regenerative's founder and CEO, Christopher Centeno, M.D., will serve as a consultant to NeoStem in the area of stem cell therapy in orthopedics and will train NeoStem personnel in mesenchymal stem cell isolation, preparation, and transplantation methods.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?